Including transgender populations in mathematical models for HIV treatment and prevention: current barriers and policy implications.
HIV
HIV policy
epidemic modelling
mathematical modelling
nonbinary
transgender
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
received:
27
01
2024
accepted:
23
05
2024
medline:
13
6
2024
pubmed:
13
6
2024
entrez:
13
6
2024
Statut:
ppublish
Résumé
Mathematical models of HIV have been uniquely important in directing and evaluating HIV policy. Transgender and nonbinary people are disproportionately impacted by HIV; however, few mathematical models of HIV transmission have been published that are inclusive of transgender and nonbinary populations. This commentary discusses current structural challenges to developing robust and accurate trans-inclusive models and identifies opportunities for future research and policy, with a focus on examples from the United States. As of April 2024, only seven published mathematical models of HIV transmission include transgender people. Existing models have several notable limitations and biases that limit their utility for informing public health intervention. Notably, no models include transgender men or nonbinary individuals, despite these populations being disproportionately impacted by HIV relative to cisgender populations. In addition, existing mathematical models of HIV transmission do not accurately represent the sexual network of transgender people. Data availability and quality remain a significant barrier to the development of accurate trans-inclusive mathematical models of HIV. Using a community-engaged approach, we developed a modelling framework that addresses the limitations of existing model and to highlight how data availability and quality limit the utility of mathematical models for transgender populations. Modelling is an important tool for HIV prevention planning and a key step towards informing public health interventions, programming and policies for transgender populations. Our modelling framework underscores the importance of accurate trans-inclusive data collection methodologies, since the relevance of these analyses for informing public health decision-making is strongly dependent on the validity of the model parameterization and calibration targets. Adopting gender-inclusive and gender-specific approaches starting from the development and data collection stages of research can provide insights into how interventions, programming and policies can distinguish unique health needs across all gender groups. Moreover, in light of the data structure limitations, designing longitudinal surveillance data systems and probability samples will be critical to fill key research gaps, highlight progress and provide additional rigour to the current evidence. Investments and initiatives like Ending the HIV Epidemic in the United States can be further expanded and are highly needed to prioritize and value transgender populations across funding structures, goals and outcome measures.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e26304Subventions
Organisme : National Institute of Allergy and Infectious Diseases
ID : F31AI152542
Organisme : American Sexually Transmitted Diseases Association
Organisme : University of Washington's School of Public Health
Organisme : National Institutes of Allergy and Infectious Disease
ID : UM1AI068617
Informations de copyright
© 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society.
Références
Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta‐analysis, 2006–2017. Am J Public Health. 2018;109(1): e1–e8. https://doi.org/10.2105/AJPH.2018.304727
Janes H, Brown MD, Glidden DV, Mayer KH, Buchbinder SP, McMahan VM, et al. Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors. PLoS One. 2019;14:e0222183. https://doi.org/10.1371/JOURNAL.PONE.0222183
Herman JL, Flores AR, O'neill KK. How many adults and youth identify as transgender in the United States? Williams Institute, UCLA School of Law; 2022.
Meerwijk EL, Sevelius JM. Transgender population size in the United States: a meta‐regression of population‐based probability samples. Am J Public Health. 2017;107:216. https://doi.org/10.2105/AJPH.2016.303578a
Stutterheim SE, van Dijk M, Wang H, Jonas KJ. The worldwide burden of HIV in transgender individuals: an updated systematic review and meta‐analysis. PLoS One. 2021;16:e0260063. https://doi.org/10.1371/JOURNAL.PONE.0260063
James SE, Herman JL, Rankin S, Keisling M, Mottet L, Anafi M. The Report of the 2015 U.S. Transgender Survey. Washington, DC: National Center for Transgender Equality; 2016.
Gonzales G, Henning‐Smith C. Barriers to care among transgender and gender nonconforming adults. Milbank Q. 2017;95:726–748. https://doi.org/10.1111/1468‐0009.12297
Macapagal K, Bhatia R, Greene GJ. Differences in healthcare access, use, and experiences within a community sample of racially diverse lesbian, gay, bisexual, transgender, and questioning emerging adults. LGBT Health. 2016;3:434–442. https://doi.org/10.1089/lgbt.2015.0124
Seelman KL, Colón‐Diaz MJ, LeCroix RH, Xavier‐Brier M, Kattari L. Transgender noninclusive healthcare and delaying care because of fear: connections to general health and mental health among transgender adults. Transgend Health. 2017;2:17–28.
Becasen JS, Morris JD, Denard CL, Mullins MM, Kota KK, Higa DH. HIV care outcomes among transgender persons with HIV infection in the United States, 2006–2021. AIDS. 2022;36:305–315. https://doi.org/10.1097/QAD.0000000000003109
Sevelius JM, Poteat T, Luhur WE, Reisner SL, Meyer IH. HIV testing and PrEP use in a national probability sample of sexually active transgender people in the United States. J Acquir Immune Defic Syndr. 2020;84(5):437–442. https://doi.org/10.1097/QAI.0000000000002403
Reisner SL, Moore CS, Asquith A, Pardee DJ, Mayer KH. The pre‐exposure prophylaxis cascade in at‐risk transgender men who have sex with men in the United States. LGBT Health. 2021;8:116–124. https://doi.org/10.1089/lgbt.2020.0232
Reisner SL, Moore CS, Asquith A, Pardee DJ, Sarvet A, Mayer G, et al. High risk and low uptake of pre‐exposure prophylaxis to prevent HIV acquisition in a national online sample of transgender men who have sex with men in the United States. J Int AIDS Soc. 2019;22:e25391. https://doi.org/10.1002/jia2.25391
Garnett GP, Cousens S, Hallett TB, Steketee R, Walker N. Mathematical models in the evaluation of health programmes. Lancet. 2011;378:515–525. https://doi.org/10.1016/S0140‐6736(10)61505‐X
Stover J. HIV models to inform health policy. Curr Opin HIV AIDS. 2011;6:108–113. https://doi.org/10.1097/COH.0b013e328343ac05
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57. https://doi.org/10.1016/S0140‐6736(08)61697‐9
90‐90‐90: an ambitious treatment target to help end the AIDS epidemic. 2014.
Jenness SM, Johnson JA, Hoover KW, Smith DK, Delaney KP. Modeling an integrated HIV prevention and care continuum to achieve the Ending the HIV Epidemic goals. AIDS. 2020;34:2103–2113. https://doi.org/10.1097/QAD.0000000000002681
Fojo AT, Schnure M, Kasaie P, Dowdy DW, Shah M. What will it take to end HIV in the United States?: a comprehensive, local‐level modeling study. Ann Intern Med. 2021;174:1542–1553. https://doi.org/10.7326/M21‐1501
Stansfield S, Heitner J, Mitchell K, Doyle CM, Milwid RM, Maheu‐Giroux M, et al. Guidelines on long‐acting injectable cabotegravir for HIV prevention: web annex D: projected population impact of expanding PrEP coverage by offering long‐acting injectable PrEP in different settings: model comparison analysis. World Health Organization; 2022.
Poteat T, Wirtz AL, Radix A, Borquez A, Silva‐Santisteban A, Deutsch MB, et al. HIV risk and preventive interventions in transgender women sex workers. Lancet. 2015;385:274–286. https://doi.org/10.1016/S0140‐6736(14)60833‐3
Gomez GB, Borquez A, Caceres CF, Segura ER, Grant RM, Garnett GP, et al. The potential impact of pre‐exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. PLoS Med. 2012;9:e1001323. https://doi.org/10.1371/journal.pmed.1001323
Melesse DY, Shafer LA, Emmanuel F, Reza T, Achakzai BK, Furqan S, et al. Heterogeneity in geographical trends of HIV epidemics among key populations in Pakistan: a mathematical modeling study of survey data. J Glob Health. 2018;8:010412. https://doi.org/10.7189/jogh.08.010412
Dimitrov D, Wood D, Ulrich A, Swan DA, Adamson B, Lama JR, et al. Projected effectiveness of HIV detection during early infection and rapid ART initiation among MSM and transgender women in Peru: a modeling study. Infect Dis Model. 2019;4:73–82. https://doi.org/10.1016/j.idm.2019.04.001
Bórquez A, Guanira JV, Revill P, Caballero P, Silva‐Santisteban A, Kelly S, et al. The impact and cost‐effectiveness of combined HIV prevention scenarios among transgender women sex‐workers in Lima, Peru: a mathematical modelling study. Lancet Public Health. 2019;4:e127–e136. https://doi.org/10.1016/S2468‐2667(18)30236‐6
Bórquez A, Rich K, Farrell M, Degenhardt L, McKetin R, Tran LT, et al. Integrating HIV pre‐exposure prophylaxis and harm reduction among men who have sex with men and transgender women to address intersecting harms associated with stimulant use: a modelling study. J Int AIDS Soc. 2020;23:e25495. https://doi.org/10.1002/jia2.25495
Brown T, Peerapatanapokin W, Siripong N, Puckett R. The AIDS epidemic model 2023 for estimating HIV trends and transmission dynamics in Asian epidemic settings. J Acquir Immune Defic Syndr. 2024;95:e13–e23. https://doi.org/10.1097/QAI.0000000000003319
Reisner SL, Poteat T, Keatley J, Cabral M, Mothopeng T, Dunham E, et al. Global health burden and needs of transgender populations: a review. Lancet. 2016;388:412–436. https://doi.org/10.1016/S0140‐6736(16)00684‐X
Baguso GN, Turner CM, Santos GM, Raymond HF, Dawson‐Rose C, Lin J, et al. Successes and final challenges along the HIV care continuum with transwomen in San Francisco. J Int AIDS Soc. 2019;22:e25270. https://doi.org/10.1002/jia2.25270
Neumann MS, Finlayson TJ, Pitts NL, Keatley JA. Comprehensive HIV prevention for transgender persons. Am J Public Health. 2017;107:207. https://doi.org/10.2105/AJPH.2016.303509
Rosen JG, Malik M, Cooney EE, Wirtz AL, Yamanis T, Lujan M, et al. Antiretroviral treatment interruptions among Black and Latina transgender women living with HIV: characterizing co‐occurring, multilevel factors using the gender affirmation framework. AIDS Behav. 2019;23(9):2588–2599. https://doi.org/10.1007/s10461‐019‐02581‐x
Kuhns LM, Reisner SL, Mimiaga MJ, Gayles T, Shelendich M, Garofalo R. Correlates of PrEP indication in a multi‐site cohort of young HIV‐uninfected transgender women. AIDS Behav. 2016;20:1470–1477. https://doi.org/10.1007/s10461‐015‐1182‐z
Sevelius JM, Deutsch MB, Grant R. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. J Int AIDS Soc. 2016;19:21105. https://doi.org/10.7448/IAS.19.7.21105
Hood JE, Eljallad T, Abad J, Connolly M, Heumann C, Fritz J, et al. Getting pre‐exposure prophylaxis to high‐risk transgender women: lessons from Detroit, USA. Sex Health. 2018;15:562–569. https://doi.org/10.1071/SH18063
Wilson EC, Jin H, Liu A, Raymond HF. Knowledge, indications and willingness to take pre‐exposure prophylaxis among transwomen in San Francisco, 2013. PLoS One. 2015;10:e0128971. https://doi.org/10.1371/journal.pone.0128971
Sevelius JM, Keatley J, Calma N, Arnold E. ‘I am not a man’: trans‐specific barriers and facilitators to PrEP acceptability among transgender women. Glob Public Health. 2016;11:1060–1075. https://doi.org/10.1080/17441692.2016.1154085
Rael CT, Martinez M, Giguere R, Bockting W, MacCrate C, Mellman W, et al. Barriers and facilitators to oral PrEP use among transgender women in New York City. AIDS Behav. 2018;22:3627–3636. https://doi.org/10.1007/s10461‐018‐2102‐9
Rael CT, Martinez M, Giguere R, Bockting W, MacCrate C, Mellman W, et al. Knowledge about oral PrEP among transgender women in New York City. AIDS Behav. 2019;23:2779–2783. https://doi.org/10.1007/s10461‐019‐02584‐8
D'Avanzo PA, Bass SB, Brajuha J, Gutierrez‐Mock L, Ventriglia N, Wellington C, et al. Medical mistrust and PrEP perceptions among transgender women: a cluster analysis. Behav Med. 2019;45:143–152. https://doi.org/10.1080/08964289.2019.1585325
Cahill SR, Keatley JA, Wade Taylor S, Sevelius J, Elsesser SA, Geffen SR, et al. “Some of us, we don't know where we're going to be tomorrow.” Contextual factors affecting PrEP use and adherence among a diverse sample of transgender women in San Francisco. AIDS Care. 2019;32(5):585–593. https://doi.org/10.1080/09540121.2019.1659912
Rowniak S, Ong‐Flaherty C, Selix N, Kowell N. Attitudes, beliefs, and barriers to PrEP among trans men. AIDS Educ Prev. 2017;29:302–314. https://doi.org/10.1521/aeap.2017.29.4.302
Koechlin FM, Fonner VA, Dalglish SL, O'Reilly KR, Baggaley R, Grant RM, et al. Values and preferences on the use of oral pre‐exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature. AIDS Behav. 2017;21:1325–1335. https://doi.org/10.1007/s10461‐016‐1627‐z
Pitasi MA, Clark HA, Chavez PR, DiNenno EA, Delaney KP. HIV testing and linkage to care among transgender women who have sex with men: 23 U.S. cities. AIDS Behav. 2020;24(8):2442–2450. https://doi.org/10.1007/s10461‐020‐02804‐6
Appenroth M, Davids J, Feuer C, Kgositau T, Mugo I. No data no more: manifesto to align HIV prevention research with trans and gender‐diverse realities. New York City: AVAC; 2021.
Restar AJ. Gender‐affirming care is preventative care. Lancet Reg Health Am. 2023;24:100544. https://doi.org/10.1016/j.lana.2023.100544
Reisner SL, Radix A, Deutsch MB. Integrated and gender‐affirming transgender clinical care and research. J Acquir Immune Defic Syndr. 2016;72(Suppl 3):S235–S242. https://doi.org/10.1097/QAI.0000000000001088
Reisner SL, Perez‐Brumer AG, McLean SA, Lama JR, Silva‐Santisteban A, Huerta L, et al. Perceived barriers and facilitators to integrating HIV prevention and treatment with cross‐sex hormone therapy for transgender women in Lima, Peru. AIDS Behav. 2017;21:3299–3311. https://doi.org/10.1007/s10461‐017‐1768‐8
Lama JR, Mayer KH, Perez‐Brumer AG, Huerta L, Sanchez H, Clark JL, et al. Integration of gender‐affirming primary care and peer navigation with HIV prevention and treatment services to improve the health of transgender women: protocol for a prospective longitudinal cohort study. J Med Internet Res. 2019;21. https://doi.org/10.2196/14091
Sevelius JM, Xavier J, Chakravarty D, Keatley J, Shade S, Rebchook G. Correlates of engagement in HIV care among transgender women of color in the United States of America. AIDS Behav. 2021;25(Suppl 1):3–12. https://doi.org/10.1007/s10461‐021‐03306‐9
Rodriguez‐Hart C, Zhao G, Goldstein Z, Radix A, Torian L. An exploratory study to describe transgender people with HIV who accessed Medicaid and their viral suppression over time in New York City, 2013–2017. Transgender Health. 2023;8:429–436. https://doi.org/10.1089/trgh.2021.0195
Summers NA, Huynh TT, Dunn RC, Cross SL, Fuchs CJ. Effects of gender‐affirming hormone therapy on progression along the HIV care continuum in transgender women. Open Forum Infect Dis. 2021;8:ofab404. https://doi.org/10.1093/ofid/ofab404
Sevelius JM, Glidden DV, Deutsch M, Welborn L, Contreras A, Salinas A, et al. Uptake, retention, and adherence to pre‐exposure prophylaxis (PrEP) in TRIUMPH: a peer‐led PrEP Demonstration Project for transgender communities in Oakland and Sacramento, California. J Acquir Immune Defic Syndr. 2021;88:S27–S38. https://doi.org/10.1097/QAI.0000000000002808
Tordoff DM, Minalga B, Perry NL, Gross B, Khosropour CM, Glick SN, et al. Heterogeneity in HIV/sexually transmitted infection prevalence and prevention among the partners of transgender and nonbinary people. Sex Transm Dis. 2023;50:280. https://doi.org/10.1097/OLQ.0000000000001796
Meyer IH, Brown TN, Herman JL, Reisner SL, Bockting WO. Demographic characteristics and health status of transgender adults in select US regions: Behavioral Risk Factor Surveillance System, 2014. Am J Public Health. 2017;107:582–589. https://doi.org/10.2105/ajph.2016.303648
Meyer IH, Wilson BDM, O'neill K. LGBTQ people in the US: select findings from the Generations and TransPop studies. Los Angeles, CA: Williams Institute; 2021. https://doi.org/10.1007/s10508‐019‐01485‐0
Feldman JL, Luhur WE, Herman JL, Poteat T, Meyer IH. Health and health care access in the US transgender population health (TransPop) survey. Andrology. 2021;9:1707–1718. https://doi.org/10.1111/ANDR.13052
Nguyen A, Katz KA, Leslie KS, Amerson EH. Inconsistent collection and reporting of gender minority data in HIV and sexually transmitted infection surveillance across the United States in 2015. Am J Public Health. 2018;108:S274–S276. https://doi.org/10.2105/AJPH.2018.304607
Centers for Disease Control and Prevention. HIV Surveillance Report, 2019. 2021.
Health Resources and Services Administration. Ryan White HIV/AIDS Program Annual Data Report, 2022. n.d.
Health Resources and Services Administration. Transgender Clients Served by the Ryan White HIV/AIDS Program, 2021. n.d.
Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV Epidemic. JAMA. 2019;321:844. https://doi.org/10.1001/jama.2019.1343
Wirtz AL, Humes E, Althoff KN, Poteat TC, Radix A, Mayer KH, et al. HIV incidence and mortality in transgender women in the eastern and southern USA: a multisite cohort study. Lancet HIV. 2023;10:e308–e319. https://doi.org/10.1016/S2352‐3018(23)00008‐5
Tordoff DM, Minalga B, Gross BB, Martin A, Caracciolo B, Barbee LA, et al. Erasure and health equity implications of using binary male/female categories in sexual health research and HIV/STI surveillance: recommendations for transgender‐inclusive data collection and reporting. Sex Transm Dis. 2021;49(2):e45–e49.
Thompson HM, Wang TM, Talan AJ, Baker KE, Restar AJ. First they came for us all: responding to anti‐transgender structural violence with collective, community‐engaged, and intersectional health equity research and advocacy. Health Educ Behav. 2023;51(1):5–9. https://doi.org/10.1177/10901981231201146
Restar A, Minalga BJ, Quilantang MI, Adamson T, Dusic E, van der Merwe L‐A, et al. Mapping community‐engaged implementation strategies with transgender scientists, stakeholders, and trans‐led community organizations. Curr HIV/AIDS Rep. 2023;20(3):160–169. https://doi.org/10.1007/s11904‐023‐00656‐y
Minalga B, Chung C, Davids JD, Martin A, Perry NL, Shook A. Research on transgender people must benefit transgender people. Lancet. 2022;399:628. https://doi.org/10.1016/S0140‐6736(21)02806‐3